Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2020-04-23 Regulatory Filings
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1383 characters) and is titled 'Second Price Monitoring Extension'. It explicitly mentions 'RNS Number : 7100K' and states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, 10-K, or IR. Since it is a regulatory announcement that doesn't fit the specific categories (like DIRS, DIV, or DLST), the most appropriate fallback category is Regulatory Filings (RNS).
2020-04-23 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1366 characters) and contains an 'RNS Number' (7086K) and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Price Monitoring Extension' for a security, which is a routine operational announcement related to trading mechanics, not a core financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement distributed via the RNS system that doesn't fit into the more specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory filing fallback category.
2020-04-23 English
EAACI review of adjuvants and formulations
Environmental & Social Information Classification · 99% confidence The document begins with an 'RNS Number' and is dated April 22, 2020. It is a brief announcement from Allergy Therapeutics plc regarding the publication of a Task Force Position Paper in the journal 'Allergy' that supports their adjuvant technology. The text is short, focuses on communicating external validation of their strategy, and concludes with contact information and a disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure strongly indicates a general regulatory news service announcement rather than a comprehensive financial report (like 10-K or IR) or a specific corporate action filing. Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIV, DIRS, ER), the most appropriate fallback is Regulatory Filings (RNS).
2020-04-22 English
Grant and Vesting of Awards
Remuneration Information Classification · 99% confidence The document begins with an 'RNS Number' and is dated April 1, 2020. The content details the 'Grant and Vesting of Awards under Long Term Incentive Plan' for Executive Directors, including specific share numbers and option grants. Crucially, the document concludes with a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them' (PDMR notification), which is a specific regulatory requirement for insider transactions. This type of filing, reporting personal share transactions by directors, directly corresponds to the 'Director's Dealing' category. The presence of the RNS header suggests it was released via a regulatory news service, but the core content is the director dealing disclosure, making DIRS the most specific classification.
2020-04-01 English
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
Report Publication Announcement Classification · 98% confidence The document is a short announcement from 'Hardman & Co Research' regarding Allergy Therapeutics (AGY). It summarizes key points from a research note ('Consistent first-half revenue growth') and explicitly directs the reader to a link to access the 'full report'. The document length is short (3886 chars), and it functions as a notification that a detailed analysis exists elsewhere. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which announces the release or availability of a report, rather than being the report itself. It is not a formal regulatory filing like a 10-K or an ER, but rather a third-party research publication announcement.
2020-03-09 English
Half-year Report
Earnings Release Classification · 100% confidence The document explicitly states it announces 'Interim Results for the six months ended 31 December 2019'. It contains detailed financial highlights (Revenue, Operating profit, R&D expenditure, Cash balance) and operational highlights for a period shorter than a year (H1 2020). This structure and content strongly align with the definition of an Interim/Quarterly Report. The presence of the RNS Number (9227E) indicates it is a regulatory filing, but the core content is the comprehensive interim financial report itself, not just an announcement of its publication. Therefore, the most specific classification is 'Interim / Quarterly Report' (IR). H1 2020
2020-03-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.